Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $3.1667.

A number of equities analysts have recently commented on INO shares. HC Wainwright reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Thursday, August 13th. Wall Street Zen raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Zacks Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 12th. Piper Sandler reaffirmed an “overweight” rating and issued a $4.00 target price on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. Finally, Jefferies Financial Group upgraded Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and increased their target price for the company from $1.80 to $3.00 in a research note on Thursday, August 13th.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $1.43 on Monday. Inovio Pharmaceuticals has a 52-week low of $0.56 and a 52-week high of $2.98. The firm has a fifty day moving average of $1.08 and a 200-day moving average of $1.26. The stock has a market capitalization of $147.86 million, a PE ratio of -1.57 and a beta of 1.63.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. Equities research analysts expect that Inovio Pharmaceuticals will post -0.72 EPS for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Eversept Partners LP acquired a new position in shares of Inovio Pharmaceuticals during the first quarter worth $1,802,000. Renaissance Technologies LLC grew its holdings in Inovio Pharmaceuticals by 16.4% during the 1st quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company’s stock valued at $1,120,000 after purchasing an additional 90,613 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Inovio Pharmaceuticals by 1,929.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 48,948 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 46,536 shares during the period. GSA Capital Partners LLP increased its stake in Inovio Pharmaceuticals by 3.8% during the 4th quarter. GSA Capital Partners LLP now owns 459,828 shares of the biopharmaceutical company’s stock worth $800,000 after buying an additional 16,724 shares during the period. Finally, Baader Bank Aktiengesellschaft acquired a new position in Inovio Pharmaceuticals in the 4th quarter worth $64,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.